Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CTSC | P53634 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078250 | 0.94 | OPRM1 (0.36) | OPRM1MEN1KMT2ACTSCKDM1A | |
| SCHEMBL1014603 | 0.74 | LTB4R (0.37) | DDB1CRBNALDH1A1HPGDHSD17B10 | |
| SCHEMBL6076968 | 0.74 | DDB1 (0.33) | DDB1CRBN | |
| SCHEMBL201288 | 0.73 | HTT (0.39) | MEN1KMT2AALDH1A1TP53MAPT | |
| SCHEMBL6077944 | 0.72 | F2 (0.33) | DDB1CRBNHTT | |
| SCHEMBL1684322 | 0.70 | ALDH1A1 (0.33) | MEN1KMT2AALDH1A1TP53MAPT | |
| SCHEMBL2396894 | 0.70 | — | — | |
| SCHEMBL5416780 | 0.69 | LTB4R (0.36) | DDB1CRBNALDH1A1HPGDHTT | |
| SCHEMBL1465576 | 0.68 | EEF2K (0.33) | KDM1AALDH1A1TP53 | |
| SCHEMBL7956678 | 0.67 | SLC6A2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112584-B2 | Nonsteroidal antiinflammatory agents | SCHERING AG (DE) | 2006-09-26 | — | — | US | disclosed |
| EP-1572671-A1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-20040209875-A1 | Nonsteroidal antiinflammatory agents | SCHERIN AKTIENGESELLSCHAFT (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004058733-A1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209875-A1 | Nonsteroidal antiinflammatory agents | PTGS1, PTGER1, PTGES | OPRM1 612/4885MEN1 1721/4885KMT2A 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.